Amalfi Bio is a clinical‑stage pharmaceutical company developing an injectable that selectively induces lipolysis in targeted fat deposits. The biomimetic formulation can be delivered minimally invasively for precise subcutaneous fat reduction in aesthetic body contouring, and also injected into peri‑organ fat to lower adipokine signaling that drives systemic diseases. This platform offers outpatient, non‑surgical treatment options for both cosmetic physicians and specialists addressing fat‑driven metabolic and organ‑specific disorders.
Funding
Funding not disclosed
Founders
Product
Problem
Current options for reducing localized fat deposits are limited to invasive surgeries like liposuction, which involve anesthesia, significant downtime, and risk of complications, as well as non‑invasive energy‑based or injectable methods that often fail to deliver consistent, targeted results. Excess peri‑organ fat also acts as an endocrine organ, releasing adipokines that contribute to systemic diseases such as cancer, hypertension, and organ‑specific disorders.
Solution
Amalfi Bio is developing a clinical‑stage injectable that selectively induces lipolysis in targeted fat deposits. The formulation is biomimetic and delivered via minimally invasive injections, enabling precise reduction of stubborn subcutaneous fat for aesthetic body contouring. The same drug platform can be administered directly into peri‑organ fat pads, decreasing their volume and the pathological signaling of adipokines that drive systemic disease progression. By targeting all adipokines locally, the therapy aims to treat disease origins without the side effects associated with systemic medications. The approach offers a non‑surgical alternative that can be performed in outpatient settings, improving patient convenience and safety.
Target Audience
Primary customers include aesthetic physicians, dermatologists, and plastic surgeons seeking precise, non‑surgical fat reduction, as well as specialists treating metabolic, oncologic, and organ‑specific diseases linked to peri‑organ adiposity.
Features
- Injectable lipolysis agent with a natural, biomimetic composition for high specificity to adipose tissue
- Minimally invasive delivery allowing precise, localized treatment of subcutaneous and peri‑organ fat
- Mechanism of action reduces volume of targeted fat and suppresses secretion of multiple adipokines simultaneously
- Designed for both aesthetic body contouring and therapeutic reduction of fat‑driven systemic disease
- Potential for outpatient administration without anesthesia, reducing procedure time and recovery